2,7-萘啶-4-甲醛 | 10273-40-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 2,7-萘啶-4-甲醛
• 英文名称: 2,7-napthyridine-4-carboxaldehyde
• 英文别名: [2,7]naphthyridine-4-carbaldehyde；4-Formyl-<2.7>naphthyridin；2.7-Naphthyridin-4-aldehyd；2,7-Naphthyridine-4-carbaldehyde
• CAS: 10273-40-2
• 化学式: C₉H₆N₂O
• 分子量: 158.159
• InChiKey: RPMGSMBPOIFFKN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  42.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  2,7-萘啶-4-甲醛 在 N-甲基咪唑 、 titanium(IV) isopropylate 、 氨 、 N,N,N',N'-tetramethylchloroformamidinium hexafluorophosphate 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 17.0h， 生成 (1R,2S,5S)-N-(cyano(2,7-naphthyridin-4-yl)methyl)-3-((S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
  参考文献：
  名称：

  [EN] INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF
  [FR] INHIBITEURS DE CYSTÉINE PROTÉASES ET LEURS MÉTHODES D'UTILISATION

  摘要：

  The disclosure provides compounds with nitrile warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with nitrile warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.

  公开号：

  WO2023044171A1
• 作为产物：
  描述：

  4-Brom-2,7-naphthyridin 在 potassium osmate(VI) dihydrate 、 dichloro[1,1'-bis(di-t-butylphosphino)ferrocene]palladium(II) 、 caesium carbonate 、 2,6-dimethyl(¹⁵N)pyridine 作用下， 以 1,4-二氧六环 、 水 、 甲苯 为溶剂， 反应 20.0h， 生成 2,7-萘啶-4-甲醛
  参考文献：
  名称：

  [EN] INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF
  [FR] INHIBITEURS DE CYSTÉINE PROTÉASES ET LEURS MÉTHODES D'UTILISATION

  摘要：

  The disclosure provides compounds with nitrile warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with nitrile warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.

  公开号：

  WO2023044171A1

文献信息

• Vilsmeier–Haack reaction of tertiary alcohols: formation of functionalised pyridines and naphthyridines
  作者：Ajith Dain Thomas、Chitoorthekkathil V. Asokan

  DOI：10.1039/b105634b

  日期：2001.10.11

  which on ammonium acetate-induced cyclisation afford 4-arylnicotinaldehydes in good yields. Tertiary alcohols derived from aliphatic or alicyclic ketones by the addition of methyl Grignard are converted into substituted pyridines and naphthyridines by the action of Vilsmeier's reagent in N,N-dimethylformamide followed by nucleophile-assisted cyclisation in the presence of ammonium acetate.

  2-芳基丙烷-2-醇的Vilsmeier-Haack反应通过多次亚氨基烷基化反应进行，导致形成共轭亚胺盐，该盐在乙酸铵诱导的环化反应中以良好的收率得到4-芳基烟碱醛。在N，N-二甲基甲酰胺中，通过Vilsmeier试剂的作用，由脂肪族或脂环族酮通过添加甲基格利雅（Grignard）衍生而来的叔醇转化为取代的吡啶和萘啶，然后在乙酸铵存在下进行亲核试剂辅助的环化反应。
• [EN] TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS<br/>[FR] COMPOSE DE BENZOPYRANNE TRICYCLIQUE EN TANT QU'AGENTS ANTI-ARRYTHMIQUES
  申请人：NISSAN CHEMICAL IND LTD

  公开号：WO2005090357A1

  公开（公告）日：2005-09-29

  This invention relates to benzopyran derivatives of formula (I) or (II), or pharmaceutically acceptable salts thereof wherein R1 and R2 are independently of each other hydrogen atom, C1-6alkyl group or C6-14aryl group, R3 is hydrogen atom or C1-6alkylcarbonyloxy group, or together with R4 forms a bond, R4 is hydrogen atom, or together with R3 forms a bond, m is an integer of 0 to 4, n is an integer of 0 to 4, V is a single bond, CR7R8, NR9, O, S, SO or SO2, R5 is hydrogen atom or C1-6alkyl group, R6 is hydrogen atom, C1-6alkyl group, C3-8cycloalkyl group, C3-8cycloalkenyl group, amino group, C1-6alkylamino group, di-C1-6alkylamino group, C6-14arylamino group, C2-9heteroarylamino group, C6-14aryl group, C2-9heteroaryl group or C2-9heterocyclyl group, A is 5-, 6- or 7-member ring fused with benzene ring, as constituent atom of the ring, oxygen atom, nitrogen atom or sulfur atom may be contained in the number of 1 to 3 alone or in a combination thereof, the number of unsaturated bond in the ring is 1, 2 or 3 including an unsaturated bond of the benzene ring to be fused, carbon atoms constituting the ring may be carbonyl or thiocarbonyl. These compounds are useful as an anti-arrhythmic agent.

  本发明涉及公式（I）或（II）的苯并吡喁衍生物，或其药学上可接受的盐，其中R1和R2分别是氢原子、C1-6烷基或C6-14芳基，R3是氢原子或C1-6烷基羰氧基，或与R4一起形成键，R4是氢原子，或与R3一起形成键，m是0到4的整数，n是0到4的整数，V是单键，CR7R8，NR9，O，S，SO或SO2，R5是氢原子或C1-6烷基，R6是氢原子，C1-6烷基，C3-8环烷基，C3-8环烯基，氨基，C1-6烷基氨基，二C1-6烷基氨基，C6-14芳基氨基，C2-9杂芳基氨基，C6-14芳基，C2-9杂芳基或C2-9杂环烷基，A是与苯环融合的5、6或7成员环，作为环的组成原子，氧原子、氮原子或硫原子可以单独或组合地包含在其中，环中的不饱和键数为1、2或3，包括与苯环融合的不饱和键，构成环的碳原子可以是羰基或硫代羰基。这些化合物可用作抗心律失常药物。
• [EN] SELECTIVE ANTI-CANCER COMPOUNDS<br/>[FR] COMPOSÉS ANTI-CANCÉREUX SÉLECTIFS
  申请人：NAT UNIV SINGAPORE

  公开号：WO2016200339A1

  公开（公告）日：2016-12-15

  A compound of formula I, wherein the compound of formula I has the structure: wherein R1 to R5, Y, L, Z and X1 to X7 have meanings given in the description, said compounds having utility in the treatment of hyperproliferative disease.

  式I的化合物，其中该化合物具有以下结构：其中R1至R5，Y，L，Z和X1至X7的含义如描述中所示，这些化合物在治疗过度增殖性疾病方面具有用途。
• Novel Hydantoin Derivatives as Metalloproteinase Inhibitors
  申请人：Gabos Balint

  公开号：US20080032997A1

  公开（公告）日：2008-02-07

  The invention provides compounds of formula (I): wherein R 1 , R 2 , A, A 1 and B are as defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy. The compounds are useful as MMP inhibitors.

  本发明提供了式(I)的化合物：其中R1、R2、A、A1和B如规范中所定义；它们的制备过程；包含它们的制药组合物；制备制药组合物的过程；以及它们在治疗中的使用。这些化合物可用作MMP抑制剂。
• Process for Producing Optically Active Chromene Oxide Compound
  申请人：Kondo Shoichi

  公开号：US20090043100A1

  公开（公告）日：2009-02-12

  [Problems] To provide an efficient process for producing an optically active chromene oxide compound which is an important intermediate for a benzopyran compound effective in the treatment of arrhythmia. [Means For Solving Problems] The process for producing an optically active chromene oxide compound comprises using an optically active titanium complex represented by, e.g., the formula (1) or (2) as a catalyst to asymmetrically oxidize an optically active chromene compound with high enantioselectivity in high chemical yield.

  [问题] 提供一种高效的生产光学活性的色兰氧化合物的方法，该化合物是治疗心律失常的苯并吡喃化合物的重要中间体。 [解决问题的方法] 生产光学活性的色兰氧化合物的方法包括使用光学活性钛配合物作为催化剂，例如使用公式（1）或（2）表示的光学活性钛配合物，以高对映选择性和高化学收率不对称氧化光学活性的色兰化合物。